Japanese researchers said on Friday that they had transplanted so-called "iPS" stem cells in the brain of a patient with Parkinson's disease, the first such trial in the world.
The team at Kyoto University injected 2.4 million pluripotent cells, capable of giving any type of cell in the left brain, during the last three months of surgery last month.
A man of fifties was well tolerated and will now be under the supervision of two years, said the University of Kyoto.
If no problem appears in the next six months, the researchers will implant 2.4 million more cells, this time in the right part of the patient's brain.
These iPS cells from healthy donors are considered to develop in neurons that produce dopamine, a neurotransmitter involved in engine control.
Kyoto University announced in July the maintenance of this clinical examination with seven participants aged between 50 and 69 years.
"I greet the patients for their courageous and determined participation"commented Professor Jun Takahashi, who announced the public television channel NHK on Friday.
Parkinson's disease marked with the tag degeneration of these neurons and results in progressive aggravation of symptoms such as jitter, extremity stiffness, and body movement decrease.
It affects more than 10 million people worldwide, according to the US Parkinson's Disease Foundation. Currently available therapies "improve the symptoms without slowing down progression of the disease"says this foundation.
This new research aims to reduce the evil.
This test follows the experiment being carried out monkeys with stem cells of human origin that enabled the ability of primates suffering from Parkinson's disease to move, according to a study published at the end of August 2017 in a science journal Nature. The survival of inserted cells, by injection into the primate brain, was observed for two years without any tumor-like appearance.
induced pluripotent stem cells (iPS for induced pluripotent stem cells), adult cells are brought back to the state near the embryonic state by re-expressing four genes (normally inactive in adult cells). this genetic manipulation gives them the ability to produce any kind of cell (pluripotency) depending on where they are transplanted in the body.
Using iPS cells is not a basic ethical problem, unlike stem cells taken from human embryos.